Dithranol (known in the U.S.A. as anthralin and in Germany as cignolin) is one of the oldest and safest topical anti-psoriatic treatments. However, despite explorative investigations, the skin disease-clearing mechanisms of dithranol remain poorly understood (Painsi et al, JDDG 2015). The purpose of this study is to investigate the therapeutic mechanisms of dithranol in psoriasis.
Skins biopsies from psoriatic skin and blood samples will be taken before (day 0) and at several time points after start (day 4, week 2-3, and week 6-7) of dithranol therapy to be subjected to an explorative analysis (see outcome measures). A total of maximal 15 psoriasis patients will be enrolled. Normal lesion-adjacent skin from 10 patients undergoing surgery for non-inflammatory conditions will serve as control.
Study Type
OBSERVATIONAL
Enrollment
27
Klinikum Klagenfurt am Woerthersee
Klagenfurt, Carinthia, Austria
Protein and mRNA expression of pro- and contra-inflammatory factors in the skin and blood
Time frame: day 0, 4, 14, 42
MicroRNA expression in skin and blood
Time frame: day 0, 4, 14, 42
Size and density of lymph and blood vessels in the skin
Time frame: day 0, 4, 14, 42
Angiogenic factors and their receptors in the skin
Time frame: day 0, 4, 14, 42
Inflammatory infiltrate in the skin and alterations of the epidermis
Time frame: day 0, 4, 14, 42
Microarray analysis of skin samples and subsequent targeted analysis of deregulated genes
Time frame: day 0, 4, 14, 42
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.